If you have heard about BPC-157, you probably heard it somewhere confident. A podcast ad read. A physical therapist's offhand comment. A forum thread where someone's rotator cuff came back faster than expected. The confidence is the problem — because the actual research record is more interesting than the sales pitch, and considerably more specific about what is known and what isn't.

Here is the honest shape of it. BPC-157 has been studied since the early 1990s. A 2025 systematic review in HSS Journal searched the literature from 1993 through 2024, identified 544 articles, screened 393 records after removing duplicates, and included 36 studies. Of those 36, 35 were preclinical and one was clinical. That ratio is the single most important fact on this page. It means the mechanistic story below — which is genuinely detailed, and in places genuinely elegant — was worked out almost entirely in rats, mice, pigs, chick embryos and cultured cells, and has barely been tested in people.

This article walks through what those studies found, in which species, using what methods, and where the gaps are. It also covers BPC-157's regulatory status, which is not simple and which a lot of sites omit. None of it is a recommendation, and none of it is medical advice.

What BPC-157 actually is

BPC-157 — Body Protection Compound-157 — is a pentadecapeptide: a chain of exactly 15 amino acids. The full sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with a molecular weight of roughly 1,419 daltons. That is small. For comparison, most growth factors are proteins many times that size.

It was identified in human gastric juice, as a fragment of a larger protective protein involved in the stomach's own defense of its lining. The version used in research and in compounded preparations is synthetic — it reproduces the naturally occurring sequence rather than being extracted from anything.

The structural detail that made researchers pay attention is the proline-rich core — three consecutive prolines, then another proline downstream. Proline's ring structure resists the proteases that would normally chew a small peptide apart. Work from the group that first described the peptide reports stability in human gastric juice for over 24 hours, and no requirement for a carrier molecule. Standard angiogenic growth factors — EGF, FGF, VEGF — degrade rapidly in acid and generally need carriers to survive administration. That comparison is the peptide's calling card in the literature. It is worth noting that the >24-hour figure comes from the originating research group's own body of work rather than from an independent replication.

One naming point that trips people up: you may see PL 14736 referred to as a related compound. It isn't. PL 14736 is a pharmaceutical development code for BPC-157 itself, from the era when the pharmaceutical company Pliva was developing it. Same molecule, different label.

How much evidence exists, and what kind

The 2025 HSS Journal systematic review is the most useful map of the field, because it counted rather than asserted.

The numbers: 544 articles identified across 1993–2024. 393 records screened after deduplication. 36 studies met inclusion criteria. Those 36 broke down as 21 mechanism studies, 14 musculoskeletal studies, 3 metabolism studies and 3 safety studies — and as 35 preclinical to 1 clinical.

The one clinical study was a retrospective review of 12 patients who received intraarticular BPC-157 for chronic knee pain. Seven of the 12 reported symptom relief lasting beyond six months. The dose used in that series was 2 cc of a 2,000 mcg/mL solution. That is the entire human efficacy record captured by the review — retrospective, uncontrolled, self-reported, and twelve people. It is not nothing. It is also not a basis for predicting what will happen to any individual, and the study parameters above are reported as study facts, not as a dosing guide.

You will frequently see the claim that "three pilot studies in humans" have been conducted — intraarticular knee injection, interstitial cystitis, and an intravenous pharmacokinetic study. That count circulates widely and is rarely cited to anything. The systematic review that searched three decades of literature found one clinical study. Where a claim and its own headline source disagree, the source wins.

One more thing to know about the sources

Much of the foundational BPC-157 literature comes from a small number of research groups — principally the Sikiric/Seiwerth group in Zagreb and the Pang group in Taiwan — who originated the peptide and have championed it since. Several of the most-cited papers are narrative reviews written by those groups, not independent trials. That does not make the findings wrong. It does mean the evidence base is narrower than the volume of publications suggests, and that independent replication is thinner than a raw citation count implies. Where this article cites those reviews, it says so.

Why species labels matter

Nearly every mechanistic finding below comes with a species attached, and this article keeps them attached deliberately. A result in a rat Achilles tendon is not a result in a human shoulder. A result in HUVEC cells — human umbilical vein endothelial cells in a dish — tells you about endothelial biology, not about a person. A chick chorioallantoic membrane assay is a classic angiogenesis screen performed on a developing egg. Sites that blur all of this into "studies show" are removing the information you most need.

How BPC-157 is thought to work

Seven mechanistic threads run through the literature. The first is by far the best evidenced; the later ones are progressively thinner.

1. Angiogenesis: acting on the receptor, not the ligand

The most rigorous mechanistic paper on BPC-157 is a 2017 study in the Journal of Molecular Medicine, and its central finding is a specificity result.

BPC-157 upregulates VEGFR2 — vascular endothelial growth factor receptor 2 — at both mRNA and protein level. It does this in rat hind-limb tissue in vivo and in cultured human endothelial cells in vitro. What it does not do is raise VEGF-A, the ligand that normally activates that receptor. In other words, it appears to work on the receiving end of the signal rather than by adding more signal. That is mechanistically distinct from simply administering VEGF, and it is the reason the peptide is described in the literature as angiomodulatory rather than as a growth factor.

Downstream, the internalized receptor time-dependently activates the VEGFR2–Akt–eNOS cascade: Akt (protein kinase B) phosphorylates endothelial nitric oxide synthase, eNOS produces nitric oxide, and nitric oxide drives vasodilation, endothelial cell migration and the assembly of new vessel structures.

Functional readouts across that paper: increased vessel density in the chick chorioallantoic membrane assay (in vivo, chick embryo); increased endothelial tube formation (in vitro, HUVEC); accelerated blood-flow recovery in rat hind-limb ischemia measured by laser Doppler; and, on histology of that ischemic muscle, higher vessel counts with enhanced vascular VEGFR2 expression.

2. The endocytosis dependency — the experiment that makes it a mechanism

This is the detail most consumer articles drop, and it is the one that turns an association into a demonstrated pathway.

BPC-157 promotes VEGFR2 internalization — the receptor is pulled inside the endothelial cell by endocytosis. The researchers then applied dynasore, an endocytosis inhibitor, and it blocked the internalization, blocked the downstream VEGFR2–Akt–eNOS activation, and abolished BPC-157-induced tube formation entirely.

That is a clean negative control. It establishes that the pro-angiogenic effect is endocytosis-dependent rather than merely correlated with receptor levels. Whatever else is uncertain about this peptide, this particular pathway was tested rather than assumed — in cultured endothelial cells.

3. The MAPK arm: ERK1/2 and the immediate-early genes

BPC-157 is reported to enhance ERK1/2 phosphorylation — extracellular signal-regulated kinase 1/2, the classic mitogen-activated protein kinase arm — in endothelial models, in a concentration-dependent way. Downstream of ERK1/2 sit the immediate-early transcription factors c-Fos, c-Jun and EGR-1, which regulate genes governing cell-cycle progression, extracellular matrix remodeling and angiogenic signaling. The cellular output described is increased proliferation, migration and tube formation.

Evidence quality note: the endothelial ERK1/2 dose-response is widely asserted and thinly cited. The strongest external support comes from the 2021 Frontiers in Pharmacology wound-healing review, which attributes the granulation tissue formation, reepithelialization, dermal remodeling and collagen deposition seen after alkali burns specifically to ERK1/2 signaling — in animal models.

4. Growth hormone receptor: sensitizing tissue rather than acting on it

This is the most conceptually interesting arm, and it comes from a 2014 Molecules paper on rat Achilles tendon fibroblasts.

When those cells were exposed to BPC-157, growth hormone receptor (GHR) turned out to be among the most abundantly upregulated genes — at both mRNA and protein level, dose-dependently and time-dependently. The magnitude is the headline: up to a sevenfold increase in GHR protein by day three.

Then the functional test. The researchers added growth hormone to BPC-157-pretreated cells. GH activated JAK2 phosphorylation time-dependently, without changing total JAK2, and increased both viable cell number and PCNA expression — a proliferation marker.

The interpretation matters: in this system BPC-157 is not behaving as a growth factor itself. It appears to make tissue more responsive to the body's own growth hormone. That is a different kind of mechanism, and a genuinely distinct idea in the peptide literature. It was demonstrated in cultured rat tendon fibroblasts.

5. Focal adhesions: FAK and paxillin

Separately, the same research group reported that BPC-157 increases phosphorylation of FAK (focal adhesion kinase) and paxillin — the core focal-adhesion complex that governs how a cell grips its substrate and how it moves.

The functional consequences reported in rat tendon: outgrowth of tendon fibroblasts from tendon explants ex vivo, improved cell survival under stress, and increased migration in vitro. These are the cellular events that would plausibly underlie the tendon healing observed in the Achilles transection model.

A citation note, because it circulates wrongly: the FAK/paxillin finding is often attributed to the 2014 Molecules GHR paper. That paper measured JAK2, not FAK/paxillin. The FAK–paxillin work is the same group's earlier tendon study (Chang et al., Journal of Applied Physiology, 2011), which the Molecules paper cites as its own reference 29.

6. Nitric oxide as a two-way system

Beyond the eNOS arm above, the Zagreb group's Gut and Liver review describes BPC-157 as modulating the nitric oxide system bidirectionally — overriding both NOS blockade and NOS overstimulation in rodent models. If that holds, it behaves less like an agonist and more like a stabiliser of nitric oxide tone. It is also the mechanistic hook these authors use to explain why the peptide's effects look similar across such different tissues.

7. Other mediator systems

The same review describes modulation of the prostaglandin system (relevant to their NSAID-lesion models), counteraction of dopamine antagonist effects, and increased serotonin release in specific brain regions — all in rodents. These sit under the authors' broader "cytoprotection/organoprotection" framing, alongside reported protection in liver, pancreas, heart and brain.

What BPC-157 has been studied for

Gastrointestinal — the deepest and oldest literature

Given where the peptide was found, this is unsurprising. Rodent work describes cytoprotective effects across the entire GI tract, in both prophylactic and therapeutic dosing designs: models of esophagitis, gastric ulceration, intestinal inflammation, and protection against alcohol- and NSAID-induced lesions.

The surgical models are the striking ones. Rat studies report healing of intestinal anastomoses and of gastrocutaneous, duodenocutaneous, colocutaneous, esophagocutaneous, vesicovaginal and rectovaginal fistulas, plus vascular as well as GI anastomoses. All rodent.

This is also the one indication that reached human trials. BPC-157, under the development code PL 14736, progressed to Phase II trials for ulcerative colitis. Those trials did not lead to an approved product, and this article does not characterize their safety or efficacy results, because the sources available here do not report them in enough detail to do so responsibly.

That gut-first history is also why BPC-157 sits under Gut Health & Digestion in the Promise catalog rather than with the recovery blends.

Musculoskeletal

The systematic review found that across preclinical injury models, BPC-157 was associated with improved functional, structural and biomechanical outcomes in muscle, tendon, ligament and bone. Fourteen of the 36 included studies were musculoskeletal, and essentially all were animal work.

The specific models: Achilles tendon transection in rats, where BPC-157 promoted ex vivo outgrowth of fibroblasts from tendon explants, improved cell survival under stress and increased migration in vitro; and rat hind-limb ischemia, where recovery of blood flow to ischemic muscle was associated with induced VEGFR2 expression and VEGFR2–Akt–eNOS activation.

Wounds and burns

The 2021 Frontiers in Pharmacology review is the fullest account, and it covers more species than most summaries admit: mice with deep burns over 20% of body area, rats with diabetic excisional wounds and fistulas, and small-type pigs with skin wounds — the pig data being the most translationally relevant, since pig skin is the standard proxy for human skin.

Mechanistically, the review describes the peptide acting across the early clotting sequence — resolution of vessel constriction, primary platelet plug formation, fibrin mesh stabilization of that plug, and resolution of the clot — followed by granulation tissue formation, reepithelialization, dermal remodeling and collagen deposition. Topical application accelerated closure after alkali burns in animals, and the review specifically notes that healing was accelerated without impairing collagen synthesis, which matters because some agents that speed closure do so at the cost of tissue quality.

Administration in these models spanned topical cream, intraperitoneal injection across a thousand-fold dose range, and oral delivery in drinking water. Observation windows ran from 3 to 72 days.

Neurological and cardiovascular

Some research has explored neurological and cardiovascular applications, though far less extensively than GI and musculoskeletal work. Treat this as an early and largely preclinical line of inquiry rather than an established application.

What the safety data covers — and what it doesn't

In animals

The systematic review reports that across preclinical models, BPC-157 was not associated with acute gross or histologic toxicity in the organs examined — liver, spleen, lung, kidney, brain, thymus, prostate, ovaries, and gastric wall. No toxic or lethal concentration was reached across a dose range spanning 6 micrograms per kilogram to 20 milligrams per kilogram — roughly a 3,300-fold span.

Two limits on that reassurance. First, it is animal data. Second, and more important: the longest observation period was under six weeks. A six-week window in a rodent tells you about acute toxicity. It does not tell you about anything that emerges over months or years.

In humans

The human safety record is thin enough to state in a sentence: one retrospective clinical study of 12 patients, plus a Phase II development program under the PL 14736 code that did not produce an approved product. That is not enough to characterize a safety profile, and this article does not claim otherwise.

Pharmacokinetics

What is known about how the body handles BPC-157, per the systematic review: a half-life of under 30 minutes, hepatic metabolism via cytochrome P450, renal excretion, and detectability in urine for four to five days. The last figure is the one athletes tend to ask about.

Long-term effects

Unknown. Almost all published work covers short-term exposure, and there is no meaningful published data on extended administration in humans. Anyone telling you long-term use is established as safe is going beyond the literature.

Regulatory status: the part most sites leave out

Three separate facts, stated plainly.

1. FDA Category 2. In 2023, the FDA placed BPC-157 in Category 2 of its review of bulk drug substances nominated for use in compounding. Category 2 is the agency's designation for nominated substances that were withdrawn from or removed from consideration for the 503A and 503B bulk substances lists because the agency identified significant safety risks. Put plainly: BPC-157 was put forward as a bulk ingredient for compounding, the FDA reviewed it, and it did not clear that review. That designation is a matter of public record.

2. Not an approved drug. BPC-157 has not been approved as a finished drug product by the FDA or by other national regulators. Anything you receive is a compounded preparation — made by a licensed compounding pharmacy against an individual prescription for an individual patient — not a manufactured, FDA-approved medication.

3. Anti-doping. The systematic review reports that BPC-157 was placed on the World Anti-Doping Agency prohibited list in 2022 and was not listed as prohibited at the time of that review's publication. Prohibited lists are revised annually. If you are subject to drug testing in any sport, check the current WADA list directly rather than relying on any article, including this one.

Those facts sit alongside the prescriber gate rather than being canceled by it. Whether BPC-157 is appropriate for a given person — in light of that regulatory status, their medical history, their current medications and what they are actually trying to address — is a clinical judgment made by a licensed provider reviewing the request. That is the point of the review.

Compounded, not off the shelf: what actually changes

Search for BPC-157 online and most of what you find is sold as a research chemical, with the buyer expected to handle it. That framing shifts a lot of technical work onto someone with no training and no accountability, and it is the clearest practical difference between a grey-market vial and a prescribed compounded preparation.

With a compounded prescription, the pharmacy owns that work:

  • The peptide arrives lyophilized — freeze-dried — because it is far more stable as a powder than in solution. Getting it back into solution correctly, with the right diluent, is a pharmacy step, not a kitchen-table step.
  • Cold chain and light protection. Lyophilized peptide is stored refrigerated at 2–8 °C or frozen, and protected from light. Reconstituted solutions have a defined stability window and a beyond-use date, which the pharmacy assigns.
  • Sterility. Sterile technique throughout preparation is what separates an injectable preparation from a contamination risk. A licensed compounding pharmacy operates under standards for this; an online reseller does not.
  • Identity and purity verification. A certificate of analysis documents purity — typically 97% or higher by HPLC — and mass spectrometry confirms that the molecule in the vial is the molecule on the label. When someone else has done this, the question "what is actually in this vial?" has a documented answer.

Promise's dispensing pharmacy partner is PerfectRx, and the preparation is dispensed only against a prescription written by a licensed provider in the Wizlo prescriber network. None of this makes the underlying evidence base stronger than it is — it addresses a different question, which is whether the thing in the vial is what it says it is and was prepared properly.

BPC-157 and TB-500

These two get discussed together constantly, so it is worth being precise about how they differ.

TB-500 is derived from thymosin beta-4, a naturally occurring actin-binding protein. Its reported mechanism centers on cell migration and differentiation — mobilizing cells toward a site of injury.

BPC-157, as described above, centers on angiogenesis — new blood vessel formation via VEGFR2 and nitric oxide — plus modulation of inflammatory mediators.

The rationale for combining them is mechanistic complementarity: one is described as improving the blood supply to an injured area, the other as helping cells get there. On paper that is a reasonable hypothesis. In published research it is largely untested. Rigorous head-to-head data comparing a combination against either compound alone is limited, and the comparative studies that exist often lack the control groups needed to say whether the combination adds anything. Promise offers combination preparations — Wolverine pairs BPC-157 with TB-500, and KLOW combines BPC-157, TB-500, GHK-Cu and KPV — and the honest position on all of them is that the combination rationale is mechanistic rather than demonstrated.

A fuller side-by-side of the two compounds — origin, mechanism, and what each literature actually measured — is in our BPC-157 vs TB-500 comparison.

What is still unknown

Setting out the gaps plainly, because they are large:

  • Human evidence. Thirty years of preclinical work has produced one clinical study in the most recent systematic review. Translation from rodent and cell-culture models to human physiology remains theoretical until trials are run.
  • Long-term safety. Observation windows in the published animal work run to under six weeks. Extended human exposure is unstudied.
  • Mechanism integration. Six or more pathways have been identified, but how they combine to produce a tissue-level outcome — and why the reported effects look so similar across such different tissues — is unresolved.
  • Independent replication. The narrowness of the research base described earlier is itself a gap. Findings from the groups that originated a compound need confirmation elsewhere.
  • Comparison against established care. Almost nothing compares BPC-157 to standard treatments for the same problems, which is the comparison a patient actually needs.

Talking to a provider about BPC-157

If you are considering BPC-157, the useful next step is a conversation with someone who can look at your specific situation — what you are trying to address, what has already been tried, your medical history, and what else you are taking.

With Promise, that conversation runs through an intake reviewed by a licensed provider in the Wizlo prescriber network. The provider decides whether a prescription is clinically appropriate. Not everyone qualifies, and a provider may decline — including on the basis of the regulatory and evidence limitations described in this article. If a prescription is written, the preparation is compounded and dispensed by a licensed pharmacy.

The preparation itself — form, specifications, and what the visit involves — is described on the BPC-157 product page.

Go into that conversation with the evidence picture from this page rather than the version from a forum thread. It is a better starting point, and it will get you a more useful answer.

References

  1. Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025;21(4):485–495. doi:10.1177/15563316251355551. Read the review
  2. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine (Berlin). 2017;95(3):323–333. doi:10.1007/s00109-016-1488-y. Read the study
  3. Chang CH, Tsai WC, Hsu YH, Su Pang JH. Pentadecapeptide BPC 157 Enhances the Growth Hormone Receptor Expression in Tendon Fibroblasts. Molecules. 2014;19(11):19066–19077. doi:10.3390/molecules191119066. Read the study
  4. Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design. 2018;24(18):1972–1989. doi:10.2174/1381612824666180712110447. Read the review
  5. Sikiric P, Hahm KB, Blagaic AB, et al. Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response. Gut and Liver. 2019;14(2):153–167. doi:10.5009/gnl18490. Read the review
  6. Seiwerth S, Milavic M, Vukojevic J, et al. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in Pharmacology. 2021;12:627533. doi:10.3389/fphar.2021.627533. Read the review
  7. Chang CH, Tsai WC, Hsu YH, Su Pang JH. Journal of Applied Physiology. 2011 — the source of the FAK/paxillin tendon findings, cited as reference 29 in the Molecules paper above.

References 4, 5 and 6 are narrative reviews authored by the research groups that originated and have championed this peptide. Reference 3 and reference 7 come from one of those groups. References 1 and 2 are independent.

Important information

This article is patient education, not medical advice. It describes what published research has reported, in the species and study designs where it was reported, and it does not predict what would happen for any individual. Nothing here is a claim that BPC-157 treats, cures or prevents any disease, and no outcome is guaranteed.

BPC-157 is not an FDA-approved drug. Preparations dispensed through Promise are compounded by a licensed pharmacy against an individual prescription. Every request is reviewed by a licensed provider in the Wizlo prescriber network. Talk to a qualified healthcare professional about your own situation before making any decision about treatment, and tell them about all medications and supplements you take.